Atsushi Fujiwara^*, Masamichi Yoshida^*, Hajime Fujimoto^†, Hiroki Nakahara^†, Kentaro Ito^‡, Kota Nishihama^§, Taro Yasuma^§, Osamu Hataji^‡, Osamu Taguchi^¶, Corina N. D’Alessandro-Gabazza^§, Esteban C. Gabazza^§, Tetsu Kobayashi^†

Oncology Research, Vol.26, No.7, pp. 1031-1036, 2018, DOI:10.3727/096504018X15151523767752

Abstract Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy of NSCLC in Japan. Osimertinib can be indicated only against T790M⁺ lung cancer as a second-line therapy. However, whether gefitinib, erlotinib, or afatinib is most appropriate as a first-line therapy is still a controversial issue. The aim of this study was to compare the effectiveness of gefitinib, erlotinib, and afatinib. We retrospectively reviewed… More >

Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu

Oncology Research, Vol.27, No.5, pp. 565-573, 2019, DOI:10.3727/096504018X15313896322888

Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of… More >

Junhui Sun^*1, Guanhui Zhou^*1, Xiaoxi Xie^†, Wenjiang Gu^‡, Jing Huang^§, Dedong Zhu^¶, Wenhao Hu^#, Qinming Hou^**, Changsheng Shi^††, Tiefeng Li^‡‡ , Xin Zhang^§§, Wenbin Ji^¶¶, Shihong Ying^§§, Zhiyi Peng^§§, Jian Zhou^##, Zhihai Yu^***, Jiansong Ji^†††, Haijun Du^‡‡‡, Xiaohua Guo^§§§, Jian Fang^¶¶¶, Jun Han^###, Huanhai Xu^****, Zhichao Sun^††††, Wenqiang Yu^‡‡‡‡, Guoliang Shao^§§§§, Xia Wu^¶¶¶¶ ,Hongjie Hu^¶¶¶¶ , Ling Li^#, Jiaping Zheng^§§§§, Jun Luo^§§§§, Yutang Chen^§§§§, Guohong Cao^####, Tingyang Hu^‡‡‡‡

Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585

Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response… More >